DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Sunday morning. The firm issued a hold rating on the stock.

DBVT has been the subject of several other reports. HC Wainwright upped their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Price Performance

DBV Technologies stock opened at $4.53 on Friday. The stock has a market cap of $93.18 million, a price-to-earnings ratio of -1.01 and a beta of 0.67. The firm has a 50-day moving average of $3.79 and a two-hundred day moving average of $3.87. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.40.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.90) by $1.10. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.17 million. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Research analysts expect that DBV Technologies will post -7.05 earnings per share for the current year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.